Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Keratorefractive surgery: a comparison of optic zone diameters

Search Title by author or title

Session Details

Session Title: Surface Photoablation/PRK

Session Date/Time: Tuesday 25/09/2018 | 14:00-16:00

Paper Time: 14:06

Venue: Room A3, Podium 2

First Author: : L.Karmona ISRAEL

Co Author(s): :    M. Mimouni   I. Vainer   T. Sela   G. Munzer   I. Kaiserman        

Abstract Details

Purpose:

To compare the efficacy, safety and accuracy of laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) with different optic zone (OZ) diameters.

Setting:

Care-Vision Laser center Institute, Tel-aviv, Israel,

Methods:

A retrospective study of consecutive eyes that underwent hyperopic LASIK, myopic PRK or myopic LASIK surgery between January 2012 and December 2016 at the Care-Vision Laser Centers, Tel-Aviv, Israel. Each surgical category was divided into 3 groups according to the diameter of the treated OZ (6.0, 6.5, 7.0 mm). Within each category, groups were compared for refractive and visual outcomes at 3 to 6 months following surgery

Results:

In hyperopic LASIK (n=594), OZ 6.0 mm demonstrated a significantly higher efficacy index , accuracy (p=0.001) and lower percent of post-operative haze (p=0.01). In myopic LASIK (n=4217), OZ 6.5 mm demonstrated a significantly higher efficacy index (p=0.001) and higher percent of post-operative dry eye (p=0.03). In myopic PRK (n=5631) OZ 7.0 demonstrated a significantly higher safety index (p=0.03), higher accuracy (p=0.03) and lower percent of post-operative haze (p=0.002). However, in multivariate analysis 6.0 mm OZ demonstrated significantly better results in all the techniques (LASIK\PRK) and refractive status (myopia\hyperopia) groups.

Conclusions:

The ideal OZ diameter is 6.0 mm and it does not differ between techniques (LASIK\PRK) and refractive status (myopia/hyperopia)

Financial Disclosure:

-

Back to previous